<DOC>
	<DOCNO>NCT00056797</DOCNO>
	<brief_summary>This study evaluate whether HIV vaccine ALVAC vCP1452 give combination interleukin-2 ( IL-2 ) , also know aldesleukin , increase immune system function people HIV infection .</brief_summary>
	<brief_title>Therapeutic HIV Vaccine Interleukin-2 Increase Immune System 's Response HIV</brief_title>
	<detailed_description>While advent highly active antiretroviral therapy ( HAART ) contribute increase control HIV infection viral replication , ultimate control HIV infection require development effective HIV-specific immunity HIV infected individual . This trial evaluate use ALVAC vCP1452 vaccine combination IL-2 increase HIV-specific immune response HIV infect patient . ALVAC vCP1452 vaccine recombinant canarypox HIV vaccine administer monthly intramuscular injection . The IL-2 self administer daily subcutaneous injection low , non-toxic dose ( 2 million unit ) . Participants study randomize receive either ALVAC IL-2 placebo first 3 month study . During time , participant continue current antiretroviral medication monthly study visit . Study visit include brief medical interview physical exam , administration vaccine , blood test . At end 3 month , participant discontinue study medication ( IL-2 ALVAC placebo ) antiretroviral medication . This Diagnostic Treatment Interruption ( DTI ) continue minimum 3 month . During DTI , participant weekly study visit viral lymphocyte dynamic monitor .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria HIV infect Stable HAART , define two antiretroviral drug combination . Changes drug allow reason virologic failure . CD4 cell count &gt; 200 cells/ml 12 month prior enrollment CD4 cell count &gt; = 400 cells/ml two successive occasion least 14 day apart within 30 day study entry HIV RNA &lt; 2 million copies/ml , suppression HAART &lt; 50 copies/ml two successive occasion least 14 day apart within 30 day entry Acceptable method contraception Exclusion Criteria Current AIDSdefining illness Virologic failure ( HIV RNA &gt; 10,000 copies/ml ) receive current HAART regimen Immunomodulating agent , include interleukin ; antibody reactive lymphocyte , monocyte , antigen present cell ; polyribonucleotides IL2 therapy within 4 week study entry Uncontrolled active cardiac , renal , pulmonary , hepatic , CNS disease History active malignancy require chemotherapy History thyroid disease autoimmune disorder , include asthma , inflammatory bowel disease , rheumatoid arthritis , psoriasis Active infection hepatitis B virus hepatitis C virus Severe retinopathy due diabetes , hypertension , CMV , macular degeneration Serious infection serious medical illness potentially life threaten require systemic therapy and/or hospitalization within 14 day study entry Substance abuse compromise participant 's ability adhere study requirement Current alcohol use 1 drink/day time 6 month prior study entry . One drink define 12 ounce beer , 5 ounce wine , 1.25 ounce hard liquor . History allergy egg , IL2 , component vaccine IL2 formulation Pregnant breastfeeding Professionals work close contact canary ( e.g. , breed farm , bird shop )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>HIV Therapeutic vaccine</keyword>
	<keyword>IL-2</keyword>
	<keyword>Structured Treatment Interruption</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>